JP2020521726A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521726A5 JP2020521726A5 JP2019559117A JP2019559117A JP2020521726A5 JP 2020521726 A5 JP2020521726 A5 JP 2020521726A5 JP 2019559117 A JP2019559117 A JP 2019559117A JP 2019559117 A JP2019559117 A JP 2019559117A JP 2020521726 A5 JP2020521726 A5 JP 2020521726A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- achieves
- dosage form
- daily dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126062 Compound A Drugs 0.000 claims description 33
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000006186 oral dosage form Substances 0.000 claims description 10
- VLCMRTMCMQJSKM-UHFFFAOYSA-N phenyl-[4-phenyl-8-(trifluoromethyl)quinolin-3-yl]methanone Chemical compound C=1C=CC=CC=1C(=O)C1=CN=C2C(C(F)(F)F)=CC=CC2=C1C1=CC=CC=C1 VLCMRTMCMQJSKM-UHFFFAOYSA-N 0.000 claims description 9
- -1 2-methoxy-3,5-dimethylpyridin-4-yl Chemical group 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 description 5
- CKJDCNZBABIEBZ-HNNXBMFYSA-N Cc(c(-c(cc1)cc(N2)c1-c([n]([C@@H]1COCC1)nc1)c1C2=O)c1C)cnc1OC Chemical compound Cc(c(-c(cc1)cc(N2)c1-c([n]([C@@H]1COCC1)nc1)c1C2=O)c1C)cnc1OC CKJDCNZBABIEBZ-HNNXBMFYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513690P | 2017-06-01 | 2017-06-01 | |
| US62/513,690 | 2017-06-01 | ||
| PCT/JP2018/020643 WO2018221546A1 (en) | 2017-06-01 | 2018-05-30 | Pharmaceutical composition comprising pde9 inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020521726A JP2020521726A (ja) | 2020-07-27 |
| JP2020521726A5 true JP2020521726A5 (https=) | 2021-07-26 |
| JP7293129B2 JP7293129B2 (ja) | 2023-06-19 |
Family
ID=64455959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559117A Active JP7293129B2 (ja) | 2017-06-01 | 2018-05-30 | Ｐｄｅ９阻害剤を含む医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11484502B2 (https=) |
| EP (1) | EP3630113A4 (https=) |
| JP (1) | JP7293129B2 (https=) |
| KR (1) | KR20200010211A (https=) |
| CN (2) | CN116585316A (https=) |
| AU (1) | AU2018276566A1 (https=) |
| BR (1) | BR112019023557A2 (https=) |
| CA (1) | CA3059539A1 (https=) |
| MX (1) | MX2019013198A (https=) |
| RU (1) | RU2019135261A (https=) |
| SG (1) | SG11201909359YA (https=) |
| WO (1) | WO2018221546A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018221550A1 (ja) | 2017-06-01 | 2018-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤 |
| RU2019135834A (ru) | 2017-06-01 | 2021-07-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила |
| BR112019023552A2 (pt) | 2017-06-01 | 2020-06-02 | Eisai R&D Management Co., Ltd. | Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina |
| WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
| CN120897742A (zh) * | 2022-11-15 | 2025-11-04 | 福睿德姆生物科学公司 | 通过抑制9型磷酸二酯酶增强血清素能致幻药物在治疗或预防某些神经精神障碍中的功效 |
| CN119302958B (zh) * | 2023-12-01 | 2025-10-21 | 郑州大学第一附属医院 | 含有bay 73-6691或其衍生物的药物制剂在制备治疗脑损伤疾病药物中的应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5318759A (en) | 1976-08-02 | 1978-02-21 | Nisshin Oil Mills Ltd | Method of making fried beancurd |
| JPH05132484A (ja) | 1991-04-26 | 1993-05-28 | Otsuka Pharmaceut Factory Inc | ピラゾロキノリン及びピラゾロナフチリジン誘導体 |
| DK0760819T3 (da) | 1994-05-24 | 2000-10-09 | Hoffmann La Roche | Tricykliske dicarbonylderivater |
| DE19642591A1 (de) | 1996-10-15 | 1998-04-16 | Basf Ag | Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung |
| HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| BR0313262A (pt) | 2002-08-07 | 2005-07-12 | Mitsubishi Pharma Corp | Compostos de dihidropirazolpiridina |
| DE10238722A1 (de) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE102004004142A1 (de) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine |
| RU2426734C2 (ru) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
| WO2005118583A1 (en) | 2004-05-28 | 2005-12-15 | Millennium Pharmaceuticals, Inc. | 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors |
| JP2006045118A (ja) | 2004-08-04 | 2006-02-16 | Mochida Pharmaceut Co Ltd | 新規ピラゾロキノロン誘導体 |
| CA2622605A1 (en) | 2005-09-15 | 2007-03-22 | Aska Pharmaceutical Co., Ltd. | Heterocycle compound, and production process and application thereof |
| CN101466365A (zh) | 2006-06-09 | 2009-06-24 | 惠氏公司 | 增强认知功能的方法 |
| TW200808741A (en) | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
| WO2008072778A1 (ja) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | 尿路系疾患の処置剤 |
| CA2671980C (en) | 2006-12-13 | 2015-05-05 | Aska Pharmaceutical Co., Ltd. | Quinoxaline derivatives |
| PT2152712E (pt) | 2007-05-11 | 2012-02-29 | Pfizer | Compostos amino-heterocíclicos |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| JP5453431B2 (ja) | 2008-09-08 | 2014-03-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用 |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| WO2010101230A1 (ja) | 2009-03-05 | 2010-09-10 | アステラス製薬株式会社 | キノキサリン化合物 |
| PE20120505A1 (es) | 2009-03-31 | 2012-05-09 | Boehringer Ingelheim Int | Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a |
| SMT201800036T1 (it) | 2009-04-13 | 2018-03-08 | Theravance Biopharma R&D Ip Llc | Combinazioni di agonisti di recettore 5-ht4 e inibitori di acetilcolinesterasi per il trattamento di disturbi cognitivi |
| US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
| AP2012006631A0 (en) | 2010-08-12 | 2012-12-31 | Boehringer Ingelheim Int | 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors |
| RS54834B1 (sr) | 2010-09-07 | 2016-10-31 | Astellas Pharma Inc | Jedinjenja pirazolokvinolina |
| US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| PT2573073E (pt) | 2011-09-26 | 2015-02-05 | Sanofi Sa | Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica |
| JP6042060B2 (ja) | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
| JP5938299B2 (ja) | 2011-10-05 | 2016-06-22 | ダイセルポリマー株式会社 | 繊維強化樹脂組成物 |
| WO2013051639A1 (ja) | 2011-10-07 | 2013-04-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体 |
| EP2982675B1 (en) | 2013-04-05 | 2017-08-16 | Eisai R&D Management Co., Ltd. | Salt of pyrazoloquinoline derivative, and crystal thereof |
| CN107847499A (zh) | 2015-05-07 | 2018-03-27 | 阿速万科学有限责任公司 | 治疗神经退行性疾病的方法 |
| BR112019023552A2 (pt) | 2017-06-01 | 2020-06-02 | Eisai R&D Management Co., Ltd. | Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina |
| RU2019135834A (ru) | 2017-06-01 | 2021-07-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила |
| WO2018221550A1 (ja) | 2017-06-01 | 2018-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤 |
-
2018
- 2018-05-30 KR KR1020197032163A patent/KR20200010211A/ko not_active Ceased
- 2018-05-30 CN CN202310559688.6A patent/CN116585316A/zh active Pending
- 2018-05-30 US US16/609,514 patent/US11484502B2/en active Active
- 2018-05-30 CA CA3059539A patent/CA3059539A1/en active Pending
- 2018-05-30 JP JP2019559117A patent/JP7293129B2/ja active Active
- 2018-05-30 SG SG11201909359Y patent/SG11201909359YA/en unknown
- 2018-05-30 RU RU2019135261A patent/RU2019135261A/ru unknown
- 2018-05-30 MX MX2019013198A patent/MX2019013198A/es unknown
- 2018-05-30 AU AU2018276566A patent/AU2018276566A1/en not_active Abandoned
- 2018-05-30 EP EP18809656.4A patent/EP3630113A4/en active Pending
- 2018-05-30 WO PCT/JP2018/020643 patent/WO2018221546A1/en not_active Ceased
- 2018-05-30 CN CN201880027744.9A patent/CN110545812A/zh active Pending
- 2018-05-30 BR BR112019023557-4A patent/BR112019023557A2/pt not_active IP Right Cessation
-
2022
- 2022-06-03 US US17/831,863 patent/US20220378706A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521726A5 (https=) | ||
| AU2016226006B2 (en) | Method of treatment with tradipitant | |
| JP2014517050A5 (https=) | ||
| RU2019134341A (ru) | (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства | |
| WO2017035405A1 (en) | Amino compounds for treatment of immune and inflammatory disorders | |
| JP2017057230A5 (https=) | ||
| FI3287124T3 (fi) | Ketamiinin oraalinen annosmuoto | |
| JP2022110143A5 (https=) | ||
| JP2021525729A5 (https=) | ||
| JP2017506624A5 (https=) | ||
| JP2002502871A5 (https=) | ||
| IL270395B (en) | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil | |
| FI3856341T3 (fi) | (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä | |
| JP2019524897A5 (https=) | ||
| JP2020521797A5 (https=) | ||
| RU2019135261A (ru) | Фармацевтическая композиция, содержащая ингибитор pde9 | |
| JP2014513065A5 (https=) | ||
| JP5738397B2 (ja) | 帯状ヘルペス疾患の治療用のオピオイド受容体拮抗薬（ナルトレキソン） | |
| JP2014513705A (ja) | 進行性固形腫瘍の治療方法 | |
| JP2011518168A5 (https=) | ||
| EP4520394A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2014517078A5 (https=) | ||
| JP2019507786A5 (https=) | ||
| JP2015516980A5 (https=) | ||
| JP2021167361A (ja) | 神経変性障害を処置するための方法 |